↓ Skip to main content

CD80+ and CD86+B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis

Overview of attention for article published in Journal of Neuroinflammation, January 2014
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
5 tweeters

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
51 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
CD80+ and CD86+B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis
Published in
Journal of Neuroinflammation, January 2014
DOI 10.1186/1742-2094-11-18
Pubmed ID
Authors

Soraya Maria Menezes, Daniele Decanine, David Brassat, Ricardo Khouri, Saul V Schnitman, Ramon Kruschewsky, Giovanni López, Carolina Alvarez, Michael Talledo, Eduardo Gotuzzo, Anne-Mieke Vandamme, Bernardo Galvão-Castro, Roland Liblau, Johan Van Weyenbergh

Abstract

Human T-cell lymphotropic virus (HTLV-1) is the causative agent of the incapacitating, neuroinflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Currently, there are no disease-modifying therapies with long-term clinical benefits or validated biomarkers for clinical follow-up in HAM/TSP. Although CD80 and CD86 costimulatory molecules play prominent roles in immune regulation and reflect disease status in multiple sclerosis (MS), data in HAM/TSP are lacking.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 2%
Unknown 50 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 22%
Student > Ph. D. Student 10 20%
Student > Master 8 16%
Student > Bachelor 7 14%
Student > Postgraduate 5 10%
Other 9 18%
Unknown 1 2%
Readers by discipline Count As %
Medicine and Dentistry 22 43%
Immunology and Microbiology 8 16%
Agricultural and Biological Sciences 8 16%
Neuroscience 2 4%
Pharmacology, Toxicology and Pharmaceutical Science 2 4%
Other 6 12%
Unknown 3 6%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 April 2021.
All research outputs
#11,311,959
of 18,974,311 outputs
Outputs from Journal of Neuroinflammation
#1,251
of 2,251 outputs
Outputs of similar age
#135,917
of 270,855 outputs
Outputs of similar age from Journal of Neuroinflammation
#14
of 20 outputs
Altmetric has tracked 18,974,311 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,251 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 270,855 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.